期刊文献+

非典型抗精神病药对精神分裂症患者超敏C反应蛋白及血脂代谢的影响 被引量:19

Effects of Atypical Anipsychotic Drugs on the High-sensitivity C-reactive Protein and Blood Lipid in Patients with Schizophrenia
下载PDF
导出
摘要 目的:探讨4种非典型抗精神病药对精神分裂症患者超敏C反应蛋白及血脂代谢的影响。方法:将115例连续住院的精神分裂症患者随机分为氯氮平组(29例)、利培酮组(29例)、奥氮平组(28例)、阿立哌唑组(29例),设正常对照组(30例)。均观察12周。在治疗前和治疗12周后分别检测各组的超敏C反应蛋白(hs-CRP)、甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)、载脂蛋白A1(APoA1)、载脂蛋白B(APoB)。测量身高和体重,并计算体质量指数(BMI)。结果:112周后氯氮平组、利培酮组、奥氮平组的hs-CPR(t=-3.512,-21.272,-3.364)、TG(t=-3.431,-3.442,-3.766)、TC(t=-3.260,-17.395,-17.626)、HDL(t=7.634,10.932,8.627)、LDL(t=-3.910,-4.339,-4.274)、BMI(t=-69.570,-33.204,-60.610)均较前有明显差异(P<0.05);奥氮平组还包括ApoB较前有明显差异(t=-3.173,P<0.05);阿立哌唑组TC(t=-18.974)、LDL(t=-3.230)、BMI(t=-4.743)较前有明显差异(P<0.05);健康对照组的各项指标较前均无明显差异(P>0.05);2治疗12周后各组通过LSD两两比较:氯氮平组、奥氮平组患者hs-CRP明显升高(P<0.05);氯氮平组、利培酮组和奥氮平组的TC、HDL明显升高(P<0.05);氯氮平组的BMI明显高于其他4组(P<0.05)。结论:氯氮平、利培酮、奥氮平均有导致hs-CPR、血脂及BMI增高的可能性,将来可能发生心血管疾病的风险也明显增高。 Objective:To explore the effects of four kinds of atypical anti-psychotic drugs on the levels of high -sensitivity C-reactive protein and blood lipid in patients with schizophrenia .Methods:115 patients with schizophreni‐a were randomly divided into four groups:Clozapine group(n=29) ,risperidone group(n=29) ,olanzapine group(n=28) ,and aripiprazole group(n=29) .Setting one control group(n=30) .The follow -up examination of each group was performed for 12 weeks .The levels of high-sensitivity C -reactive protein(hs-CRP) ,triglyceride(TG) ,total chole-sterol(TC) ,high-density lipoprotei ,n(HDL) ,low -density lipoprotein(LDL) ,apolipoproteinA1(APoA1) , apolipoproteinB(APoB)were measured before and after the treatment course ,respectively .The waist circumference , height and weight were also measured to evaluate the body mass index(BMI) .Results:① After 12 weeks ,the levels of hs-CRP(t=‐3 5.12 ,‐21 2.72 ,‐3 3.64) ,TG(t=‐3 4.31 ,‐3 4.42 ,‐3 7.66) ,TC(t=‐3 2.60 ,‐17 3.95 ,‐17 6.26) ,HDL(t=7 6.34 ,10 9.32 ,8 6.27) ,LDL(t=‐3 9.10 ,‐4 3.39 ,‐4 2.74) ,BMI(t=‐69 5.70 ,‐33 2.04 ,‐60 6.10)in clozapine group ,risperi‐done group and olanzapine group ,showed clear differences(P〈0 0.5) ,compared with those before tre-atment .The levels of ApoB in olanzapine group were obviously different compared with that before treatment(t=‐3 .173 P〈0 0.5) .The levels of TC(t=‐18 9.74) ,LDL(t=‐3 2.30) ,BMI(t=‐4 7.43)in aripiprazole group were obviously different compared with that before treatment(P0 0.5) .② After 12 weeks ,the levers of hs-CRP in clozapine group and olanzapine group were higher than other groups(P〈0 0.5) .The levels of TC ,HDL in clozapine group ,risperidone group and olanzapine group increased significantly(P〈0 0.5) .The levels of BMI in clozapine group was significantly higher than those in the other groups (P〈0 0.5) .Conclusion:The levels of high -sensitivity C -reactive protein ,blood lipid and body mass index in pa‐tients with schizophrenia are increased by the three factors(clozapine ,risperidone ,olanzapine) .The risk of cardiovas‐cular disease may also significantly increased in the future .
出处 《中国健康心理学杂志》 2016年第6期816-820,共5页 China Journal of Health Psychology
关键词 非典型抗精神病药 超敏C反应蛋白 血脂 精神分裂症 Atypical antipsychotic drugs High-sensitivity C-reactive protein Blood lipid Schizophrenia
  • 相关文献

参考文献17

二级参考文献54

  • 1庄一义.载脂蛋白A1和B的参考值及临床意义[J].中国动脉硬化杂志,2006,14(3):263-266. 被引量:35
  • 2Tschoner A, Engl J, Laimer M, et al. Metabolic side effects of antipsychotic medication. Internation journal of clinical practice, 2007,61 (8) : 1356.
  • 3Rizzo M, Corrado E, Coppola G, et al. Prediction of cerebrovascular and cardiovascular events in patients with subclinical carotid atherosclerosis: the rele of C -reactive protein. J Investig Med,2008,56:32.
  • 4Ridker P M. Clinical application of C - reactive protein for cardiovascular disease detection and prevention. Circulation,2003,107:363.
  • 5Kendler K S, Gatz M, Gander C O, et al. A sewedish national in study of life time major depression. Am J Psychiatry, 2006,163:109.
  • 6Laurie Barclay. Aripiprazole saf, effective in schizophrenia. Schizoaffectire Disorder,2003,60:681.
  • 7吴仁容,赵靖平,邵平,何益群,房茂胜,刘毅君,国效峰.二甲双胍联合行为干预治疗抗精神病药所致体质量增加及糖代谢紊乱的研究[J].中华精神科杂志,2007,40(4):193-196. 被引量:17
  • 8回秀清,彭祖贵.奥氮平治疗急性期精神病的临床疗效观察[J].中国健康心理学杂志,2007,15(12):1112-1113. 被引量:6
  • 9Coccurello R,Moles A.Potential mechanisms of atypical antipsychotic-induced metabolic derangement:Clues for understanding obesity and novel drug design[J].Pharmacology&Therapeutics,2010,127(3):210-251.
  • 10Alberti K,Zimmet P,Shaw J.Metabolic syndrome-a new world‐wide definition.A Consensus Statement from the International Diabetes Federation[J].Diabetic Medicine,2006,23(5):469-480.

共引文献94

同被引文献176

引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部